News | June 21, 2025
Biocon concludes a Rs 4,500 crore equity fundraise through QIP
The proceeds from the QIP will be utiized for purchase of outstanding optionally convertible debentures
The proceeds from the QIP will be utiized for purchase of outstanding optionally convertible debentures
his is the second license extension of a Nurix autoimmune disease program by Sanofi in the last 90 days
The approval is for the generic version of Victoza, indicated for the treatment of insufficiently controlled Type 2 Diabetes Mellitus
Adds fast-growing and only approved medicine for advanced and indolent systemic mastocytosis to the Sanofi portfolio
Sun Pharma will invest up to $25 million in US-based Pharmazz Inc, raising its stake to 22.7%
3SBio will receive an upfront payment of $1.25 billion and is eligible to receive milestone payments associated with certain development, regulatory and commercial milestones up to $4.8 billion
Planned acquisition will strengthen the presence of Merck Healthcare in the United States and expand reach of SpringWorks’ therapeutic innovations to more patients with rare tumors worldwide
Fexuprazan has the longest half-life of 9 hours among potassium-competitive acid blockers
He has global experience in strategic and operational leadership levels with an extensive track record of leadership and success in building companies, businesses, teams, and brands for over 30 years
Bio-Thera will maintain responsibility for development, manufacturing, and supply of BAT2206 and BAT2506
Subscribe To Our Newsletter & Stay Updated
